questionsmedicales.fr
Composés polycycliques
Hydrocarbures aromatiques polycycliques
Benzocycloheptènes
Benzocycloheptènes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Spectroscopie
Chromatographie
Tests de toxicité
Efficacité
Analyse sanguine
Échantillons biologiques
Marqueurs biologiques
Exposition
Imagerie moléculaire
Distribution tissulaire
Symptômes
5
Effets secondaires
Réactions allergiques
Symptômes neurologiques
Troubles de la coordination
Éruptions cutanées
Réaction allergique
Système respiratoire
Irritations
Prévention
5
Équipements de protection
Protocoles de sécurité
Milieu industriel
Exposition
Réglementations
Usage industriel
Évaluation des risques
Environnements de travail
Traitements
5
Intoxication
Soins symptomatiques
Antidotes
Composés chimiques
Antihistaminiques
Réactions allergiques
Hospitalisation
Symptômes graves
Suivi médical
Effets à long terme
Complications
5
Complications
Lésions organiques
Cancers
Potentiel cancérigène
Effets sur la reproduction
Études animales
Allergies
Sensibilisations
Système immunitaire
Infections
Facteurs de risque
5
Travailleurs
Industrie chimique
Prédispositions génétiques
Sensibilité aux toxines
Antécédents médicaux
Allergies
Environnement de travail
Ventilation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Benzocycloheptènes : Questions médicales les plus fréquentes",
"headline": "Benzocycloheptènes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Benzocycloheptènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-11",
"dateModified": "2025-03-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hydrocarbures aromatiques polycycliques",
"url": "https://questionsmedicales.fr/mesh/D011084",
"about": {
"@type": "MedicalCondition",
"name": "Hydrocarbures aromatiques polycycliques",
"code": {
"@type": "MedicalCode",
"code": "D011084",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Dibenzocycloheptènes",
"alternateName": "Dibenzocycloheptenes",
"url": "https://questionsmedicales.fr/mesh/D003986",
"about": {
"@type": "MedicalCondition",
"name": "Dibenzocycloheptènes",
"code": {
"@type": "MedicalCode",
"code": "D003986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Amitriptyline",
"alternateName": "Amitriptyline",
"url": "https://questionsmedicales.fr/mesh/D000639",
"about": {
"@type": "MedicalCondition",
"name": "Amitriptyline",
"code": {
"@type": "MedicalCode",
"code": "D000639",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Butaclamol",
"alternateName": "Butaclamol",
"url": "https://questionsmedicales.fr/mesh/D002069",
"about": {
"@type": "MedicalCondition",
"name": "Butaclamol",
"code": {
"@type": "MedicalCode",
"code": "D002069",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.230"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cyproheptadine",
"alternateName": "Cyproheptadine",
"url": "https://questionsmedicales.fr/mesh/D003533",
"about": {
"@type": "MedicalCondition",
"name": "Cyproheptadine",
"code": {
"@type": "MedicalCode",
"code": "D003533",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Maléate de dizocilpine",
"alternateName": "Dizocilpine Maleate",
"url": "https://questionsmedicales.fr/mesh/D016291",
"about": {
"@type": "MedicalCondition",
"name": "Maléate de dizocilpine",
"code": {
"@type": "MedicalCode",
"code": "D016291",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.380"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nortriptyline",
"alternateName": "Nortriptyline",
"url": "https://questionsmedicales.fr/mesh/D009661",
"about": {
"@type": "MedicalCondition",
"name": "Nortriptyline",
"code": {
"@type": "MedicalCode",
"code": "D009661",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.535"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protriptyline",
"alternateName": "Protriptyline",
"url": "https://questionsmedicales.fr/mesh/D011530",
"about": {
"@type": "MedicalCondition",
"name": "Protriptyline",
"code": {
"@type": "MedicalCode",
"code": "D011530",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.650"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes",
"alternateName": "Benzocycloheptenes",
"code": {
"@type": "MedicalCode",
"code": "D001567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jiatian Li",
"url": "https://questionsmedicales.fr/author/Jiatian%20Li",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Xiangwen Tan",
"url": "https://questionsmedicales.fr/author/Xiangwen%20Tan",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Huanfeng Jiang",
"url": "https://questionsmedicales.fr/author/Huanfeng%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Wanqing Wu",
"url": "https://questionsmedicales.fr/author/Wanqing%20Wu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Heparin and heparin proteoglycan-mimetics activate platelets via PEAR1 and PI3Kβ.",
"datePublished": "2022-12-22",
"url": "https://questionsmedicales.fr/article/36695374",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtha.2022.10.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Heparin-Induced Thrombocytopenia].",
"datePublished": "2024-05-31",
"url": "https://questionsmedicales.fr/article/38841785",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18087/cardio.2024.5.n2186"
}
},
{
"@type": "ScholarlyArticle",
"name": "Heparin Induced Thrombocytopenia Testing.",
"datePublished": "2024-05-30",
"url": "https://questionsmedicales.fr/article/39089757",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cll.2024.04.013"
}
},
{
"@type": "ScholarlyArticle",
"name": "Heparin Rebound: An In-Depth Review.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36641308",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.jvca.2022.12.019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients.",
"datePublished": "2022-06-15",
"url": "https://questionsmedicales.fr/article/35716998",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jvsv.2022.04.019"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Benzocycloheptènes",
"item": "https://questionsmedicales.fr/mesh/D001567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Benzocycloheptènes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Benzocycloheptènes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Benzocycloheptènes",
"description": "Comment identifier les benzocycloheptènes ?\nQuels tests sont utilisés pour les benzocycloheptènes ?\nLes benzocycloheptènes sont-ils détectables dans le sang ?\nY a-t-il des marqueurs spécifiques pour ces composés ?\nPeut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Heparin#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Benzocycloheptènes",
"description": "Quels sont les effets secondaires des benzocycloheptènes ?\nLes benzocycloheptènes causent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nPeut-on observer des symptômes cutanés ?\nLes benzocycloheptènes affectent-ils le système respiratoire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Heparin#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Benzocycloheptènes",
"description": "Comment prévenir l'exposition aux benzocycloheptènes ?\nY a-t-il des formations pour manipuler ces composés ?\nQuels sont les risques en milieu industriel ?\nDes réglementations existent-elles pour leur usage ?\nComment évaluer les risques d'exposition ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Heparin#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Benzocycloheptènes",
"description": "Comment traiter une intoxication aux benzocycloheptènes ?\nY a-t-il des antidotes pour ces composés ?\nQuels médicaments peuvent aider en cas d'allergie ?\nLes benzocycloheptènes nécessitent-ils une hospitalisation ?\nComment gérer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Heparin#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Benzocycloheptènes",
"description": "Quelles complications peuvent survenir avec ces composés ?\nLes benzocycloheptènes peuvent-ils causer des cancers ?\nY a-t-il des effets sur la reproduction ?\nPeut-on développer des allergies à long terme ?\nLes benzocycloheptènes affectent-ils le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Heparin#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Benzocycloheptènes",
"description": "Qui est le plus à risque d'exposition ?\nL'âge influence-t-il la sensibilité ?\nY a-t-il des prédispositions génétiques ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement de travail influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Heparin#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les benzocycloheptènes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques de spectroscopie et de chromatographie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les benzocycloheptènes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de toxicité et d'efficacité sont réalisés en laboratoire."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes sont-ils détectables dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour ces composés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs biologiques peuvent indiquer l'exposition à ces composés."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des benzocycloheptènes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes causent-ils des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs peuvent survenir en cas de toxicité ou d'allergie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent survenir en cas de réaction allergique."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système respiratoire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition excessive peut entraîner des irritations respiratoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition aux benzocycloheptènes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des formations pour manipuler ces composés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des formations spécifiques sont souvent requises pour les chercheurs."
}
},
{
"@type": "Question",
"name": "Quels sont les risques en milieu industriel ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate."
}
},
{
"@type": "Question",
"name": "Des réglementations existent-elles pour leur usage ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques d'exposition ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail."
}
},
{
"@type": "Question",
"name": "Comment traiter une intoxication aux benzocycloheptènes ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antidotes pour ces composés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent aider en cas d'allergie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes nécessitent-ils une hospitalisation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hospitalisation peut être nécessaire en cas de symptômes graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier est recommandé pour surveiller les effets à long terme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces composés ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes peuvent-ils causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets sur la reproduction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets néfastes sur la reproduction ont été observés dans certaines études animales."
}
},
{
"@type": "Question",
"name": "Peut-on développer des allergies à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des sensibilisations peuvent se développer avec une exposition répétée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en laboratoire et en industrie chimique sont les plus exposés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la sensibilité ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement de travail influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement de travail mal ventilé augmente le risque d'exposition."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 08/03/2025
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
Platelet endothelial aggregation receptor 1 (PEAR1) is a single-transmembrane orphan receptor primarily expressed on platelets and endothelial cells. Genetic variants of PEAR1 have repeatedly and inde...
We have identified sulfated fucoidans and their mimetics as ligands for PEAR1 and proposed that its endogenous ligand is a sulfated proteoglycan. The aim of this study was to test this hypothesis....
A heparin proteoglycan-mimetic (HPGM) was created by linking unfractionated heparin (UFH) to albumin. The ability of the HPGM, UFH and selectively desulfated heparins to stimulate platelet aggregation...
We show that HPGM, heparin conjugated to an albumin protein core, stimulates aggregation and phosphorylation of PEAR1 in washed platelets. Platelet aggregation was abolished by an anti-PEAR1 nanobody,...
Our findings reveal that PEAR1 is a receptor for heparin and HPGM and that PI3Kβ is a key signaling molecule downstream of PEAR1 in platelets. These findings may have important implications for our un...
The extensive use of therapeutic doses of heparin to prevent thrombosis in critically ill patients with COVID-19 during the pandemic has led to an increased incidence of bleeding and heparin-induced t...
This article provides a comprehensive overview of Heparin-Induced Thrombocytopenia (HIT) with an emphasis on laboratory testing and advantages of automation. HIT is a critical condition arising from h...
The common conception of "heparin rebound" invokes heparin returning to circulation in the postoperative period after apparently adequate intraoperative reversal with protamine. This is believed to po...
Thrombosis in COVID-19 worsens mortality. In our study, we sought to investigate how the dose and type of anticoagulation (AC) can influence patient outcomes....
This is a single-center retrospective analysis of critically ill intubated patients with COVID-19, comparing low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) at therapeutic and pro...
Overall, therapeutic AC, with either LMWH (65% vs 79%, P = .09) or UFH (32% vs 46%, P = .73), conveyed no survival benefit over prophylactic AC. UFH was associated with a higher mortality rate than LM...
Among intubated critically ill COVID-19 intensive care unit patients, therapeutic AC, with either LMWH or UFH, conveyed no survival benefit over prophylactic AC. AC with LMWH was associated with highe...
Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100 years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence, which potentiates the...
Heparin, a sulfate-containing linear polysaccharide, has proven preclinical and clinical efficacy for a variety of disorders. Heparin, including unfractionated heparin (UFH), low-molecular-weight hepa...
We present a thermodynamic investigation of the interaction of heparin with lysozyme in the presence of potassium glutamate (KGlu). The binding constant...
To explore the difference in post-operative DVT, PE, and ICH complications following administration of prophylactic UFH or enoxaparin in patients undergoing craniotomy....
A retrospective chart review was conducted for 542 patients at our institution receiving either 5000units/0.5 mL UFH (BID or TID; 180 patients) or single daily 40 mg/0.4 mL enoxaparin (362 patients) f...
Patients receiving prophylactic enoxaparin, when compared to UFH, exhibited similar rates of postoperative DVT (22 % vs 20.6 %, p = 0.86), PE (9.7 % vs 8.9 %, p = 0.86), and reoperation for bleeding (...
In patients undergoing craniotomy, rates for DVT, PE, and ICH were similar between patients treated with either prophylactic enoxaparin or UFH. Further studies are needed to understand whether a certa...
Orthopedic and dental implants coated with fibroblast growth factor-2 (FGF-2)-calcium phosphate composite layers promote dermis formation, bone formation, and angiogenesis because of the biological ac...